Premium
Use of resveratrol and quercetin combination as potential therapeutic for treatment of in‐stent restenosis and thrombosis
Author(s) -
Khandelwal Alok Radheyshyam,
Hebert Valeria,
Dugas Tammy R
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.640.4
Subject(s) - restenosis , medicine , resveratrol , thrombosis , neointimal hyperplasia , angioplasty , platelet , pharmacology , platelet activation , bare metal stent , cardiology , drug eluting stent , stent , endocrinology
Recent epidemiological studies suggest restenosis and acute in‐stent thrombosis as important complications of carotid angioplasty and stenting. Our objective was to identify a drug combination that would inhibit both restenosis and thrombosis. We studied two red wine polyphenols, resveratrol (RESV) and quercetin (QUER) that emerged as lead candidates in our prior in vitro studies using platelets and vascular smooth muscle cells. B6.129 female mice were fed a high fat diet containing RESV (50 mg/kg), QUER (10 mg/kg) and RESV plus QUER for 2 weeks. The carotid artery denudation procedure was performed and the mice were again administered the high fat diet‐containing polyphenols for 2 weeks. After sacrifice, the carotid arteries were excised for morphometric analysis and serum, collected for measurement of TXB2 as a marker for platelet activation. Our results indicate RESV, but not QUER, significantly decreased the restenotic index (p<0.05). Interestingly, with combination treatment, QUER potentiated RESV‐mediated decrease in neointimal hyperplasia (p<0.01). Conversely, QUER, but not RESV, significantly decreased serum TXB2 levels, with RESV potentiating the effects of QUER (p<0.01). In conclusion, our studies suggest that in combination, RESV and QUER can synergize to effectively reduce the pathogenesis of restenosis. Future implications include the use of this drug combination in drug eluting stents. Grant Funding Source RO1‐ HL082472